Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103

Identifieur interne : 002547 ( Main/Exploration ); précédent : 002546; suivant : 002548

F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103

Auteurs : Chantal Etiévant ; Anna Kruczynski ; Jean-Marc Barret ; Dominique Perrin ; Benoît Van Hille ; Yves Guminski ; Bridget T. Hill

Source :

RBID : ISTEX:BCEF31C2A7910CDD5ABCECF49FBACCED70E8838C

English descriptors

Abstract

Abstract: Purpose: F 11782 (2′′,3′′-bis pentafluorophenoxyacetyl-4′′,6′′-ethylidene-β-d-glucoside of 4′-phosphate-4′-dimethylepipodophyllotoxin, di-N-methyl glucamine salt) is a newly synthesized dual catalytic inhibitor of topoisomerases I and II with major in vivo antitumour activity. In this study, we compared and contrasted F 11782 with three other known inhibitors of both these nuclear enzymes, namely aclarubicin, intoplicin and TAS-103, and established its novel mechanism of action. Methods: In vitro growth-inhibitory effects against a panel of murine and tumour cell lines were measured by cell counting, clonogenicity or tetrazolium metabolic dye (MTT) assays. In vivo antitumour activities were evaluated against two murine tumour models (i.v. P388 leukaemia and s.c. B16 melanoma). Finally, interactions with either DNA or DNA-topoisomerases were determined using various methodologies: DNA-intercalator displacement, pBR322 DNA relaxation, kDNA decatenation, topoisomerase II extractability measurements, stabilization of topoisomerase-induced cleavable complexes (CC) in vitro and in cells, and gel retardation assays. Results: F 11782 had a different profile of sensitivities and proved generally less cytotoxic than the other dual inhibitors tested in vitro, while showing significantly superior antitumour activity in vivo. F 11782, which did not stabilize CC either in vitro or in cells, was the only compound of this series capable of inhibiting the catalytic activity of both DNA-topoisomerases without interacting with DNA, and of completely impairing the binding of these nuclear proteins to DNA. Moreover, only cotreatment of cells in vitro with F 11782 enhanced the cytotoxic activity of etoposide. Conclusion: These results emphasize the novel mechanism of action of F 11782 vis-à-vis the other dual inhibitors of topoisomerases I and II and so augur well for its future clinical development.

Url:
DOI: 10.1007/s002800000133


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103</title>
<author>
<name sortKey="Etievant, Chantal" sort="Etievant, Chantal" uniqKey="Etievant C" first="Chantal" last="Etiévant">Chantal Etiévant</name>
</author>
<author>
<name sortKey="Kruczynski, Anna" sort="Kruczynski, Anna" uniqKey="Kruczynski A" first="Anna" last="Kruczynski">Anna Kruczynski</name>
</author>
<author>
<name sortKey="Barret, Jean Marc" sort="Barret, Jean Marc" uniqKey="Barret J" first="Jean-Marc" last="Barret">Jean-Marc Barret</name>
</author>
<author>
<name sortKey="Perrin, Dominique" sort="Perrin, Dominique" uniqKey="Perrin D" first="Dominique" last="Perrin">Dominique Perrin</name>
</author>
<author>
<name sortKey="Van Hille, Benoit" sort="Van Hille, Benoit" uniqKey="Van Hille B" first="Benoît" last="Van Hille">Benoît Van Hille</name>
</author>
<author>
<name sortKey="Guminski, Yves" sort="Guminski, Yves" uniqKey="Guminski Y" first="Yves" last="Guminski">Yves Guminski</name>
</author>
<author>
<name sortKey="Hill, Bridget T" sort="Hill, Bridget T" uniqKey="Hill B" first="Bridget T." last="Hill">Bridget T. Hill</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BCEF31C2A7910CDD5ABCECF49FBACCED70E8838C</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1007/s002800000133</idno>
<idno type="url">https://api.istex.fr/ark:/67375/VQC-4QWQ6BSC-C/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001355</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001355</idno>
<idno type="wicri:Area/Istex/Curation">001355</idno>
<idno type="wicri:Area/Istex/Checkpoint">001365</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001365</idno>
<idno type="wicri:doubleKey">0344-5704:2000:Etievant C:f:a:dual</idno>
<idno type="wicri:Area/Main/Merge">002575</idno>
<idno type="wicri:Area/Main/Curation">002547</idno>
<idno type="wicri:Area/Main/Exploration">002547</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103</title>
<author>
<name sortKey="Etievant, Chantal" sort="Etievant, Chantal" uniqKey="Etievant C" first="Chantal" last="Etiévant">Chantal Etiévant</name>
<affiliation>
<wicri:noCountry code="subField">FR</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Kruczynski, Anna" sort="Kruczynski, Anna" uniqKey="Kruczynski A" first="Anna" last="Kruczynski">Anna Kruczynski</name>
<affiliation>
<wicri:noCountry code="subField">FR</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Barret, Jean Marc" sort="Barret, Jean Marc" uniqKey="Barret J" first="Jean-Marc" last="Barret">Jean-Marc Barret</name>
<affiliation>
<wicri:noCountry code="subField">FR</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Perrin, Dominique" sort="Perrin, Dominique" uniqKey="Perrin D" first="Dominique" last="Perrin">Dominique Perrin</name>
<affiliation>
<wicri:noCountry code="subField">FR</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Van Hille, Benoit" sort="Van Hille, Benoit" uniqKey="Van Hille B" first="Benoît" last="Van Hille">Benoît Van Hille</name>
<affiliation>
<wicri:noCountry code="subField">FR</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Guminski, Yves" sort="Guminski, Yves" uniqKey="Guminski Y" first="Yves" last="Guminski">Yves Guminski</name>
<affiliation>
<wicri:noCountry code="subField">FR</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Hill, Bridget T" sort="Hill, Bridget T" uniqKey="Hill B" first="Bridget T." last="Hill">Bridget T. Hill</name>
<affiliation>
<wicri:noCountry code="subField">FR</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Cancer Chemotherapy and Pharmacology</title>
<title level="j" type="abbrev">Cancer Chemother Pharmacol</title>
<idno type="ISSN">0344-5704</idno>
<idno type="eISSN">1432-0843</idno>
<imprint>
<publisher>Springer-Verlag</publisher>
<pubPlace>Berlin/Heidelberg</pubPlace>
<date type="published" when="2000-08-01">2000-08-01</date>
<biblScope unit="volume">46</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="101">101</biblScope>
<biblScope unit="page" to="113">113</biblScope>
</imprint>
<idno type="ISSN">0344-5704</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0344-5704</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>AbbreviationsCC cleavable complexes</term>
<term>DMSO dimethyl sulphoxide</term>
<term>DTT dithiothreitol</term>
<term>Dual inhibitors</term>
<term>EC effective concentration</term>
<term>FCS fetal calf serum</term>
<term>In vitro</term>
<term>In vivo</term>
<term>Key words F 11782</term>
<term>MCC minimally cytotoxic concentration</term>
<term>MTT 3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide</term>
<term>PBS phosphate buffered saline</term>
<term>PCR polymerase chain reaction</term>
<term>RE real effect</term>
<term>SDS sodium dodecyl sulphate</term>
<term>TA theoretical additivity</term>
<term>Topoisomerases</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Purpose: F 11782 (2′′,3′′-bis pentafluorophenoxyacetyl-4′′,6′′-ethylidene-β-d-glucoside of 4′-phosphate-4′-dimethylepipodophyllotoxin, di-N-methyl glucamine salt) is a newly synthesized dual catalytic inhibitor of topoisomerases I and II with major in vivo antitumour activity. In this study, we compared and contrasted F 11782 with three other known inhibitors of both these nuclear enzymes, namely aclarubicin, intoplicin and TAS-103, and established its novel mechanism of action. Methods: In vitro growth-inhibitory effects against a panel of murine and tumour cell lines were measured by cell counting, clonogenicity or tetrazolium metabolic dye (MTT) assays. In vivo antitumour activities were evaluated against two murine tumour models (i.v. P388 leukaemia and s.c. B16 melanoma). Finally, interactions with either DNA or DNA-topoisomerases were determined using various methodologies: DNA-intercalator displacement, pBR322 DNA relaxation, kDNA decatenation, topoisomerase II extractability measurements, stabilization of topoisomerase-induced cleavable complexes (CC) in vitro and in cells, and gel retardation assays. Results: F 11782 had a different profile of sensitivities and proved generally less cytotoxic than the other dual inhibitors tested in vitro, while showing significantly superior antitumour activity in vivo. F 11782, which did not stabilize CC either in vitro or in cells, was the only compound of this series capable of inhibiting the catalytic activity of both DNA-topoisomerases without interacting with DNA, and of completely impairing the binding of these nuclear proteins to DNA. Moreover, only cotreatment of cells in vitro with F 11782 enhanced the cytotoxic activity of etoposide. Conclusion: These results emphasize the novel mechanism of action of F 11782 vis-à-vis the other dual inhibitors of topoisomerases I and II and so augur well for its future clinical development.</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Barret, Jean Marc" sort="Barret, Jean Marc" uniqKey="Barret J" first="Jean-Marc" last="Barret">Jean-Marc Barret</name>
<name sortKey="Etievant, Chantal" sort="Etievant, Chantal" uniqKey="Etievant C" first="Chantal" last="Etiévant">Chantal Etiévant</name>
<name sortKey="Guminski, Yves" sort="Guminski, Yves" uniqKey="Guminski Y" first="Yves" last="Guminski">Yves Guminski</name>
<name sortKey="Hill, Bridget T" sort="Hill, Bridget T" uniqKey="Hill B" first="Bridget T." last="Hill">Bridget T. Hill</name>
<name sortKey="Kruczynski, Anna" sort="Kruczynski, Anna" uniqKey="Kruczynski A" first="Anna" last="Kruczynski">Anna Kruczynski</name>
<name sortKey="Perrin, Dominique" sort="Perrin, Dominique" uniqKey="Perrin D" first="Dominique" last="Perrin">Dominique Perrin</name>
<name sortKey="Van Hille, Benoit" sort="Van Hille, Benoit" uniqKey="Van Hille B" first="Benoît" last="Van Hille">Benoît Van Hille</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002547 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002547 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:BCEF31C2A7910CDD5ABCECF49FBACCED70E8838C
   |texte=   F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021